Related Experiment Video
Updated: Jun 10, 2026
Nuclear Isolation from Cryopreserved In Vitro Derived Blood Cells
Published on: March 15, 2024
Cryoprecipitate utilization in the neonatal intensive care unit: a single-center review
Ashley Stoeckel1, Erin Soule-Albridge2, Henry A Feldman3
1Boston Children's Hospital, Department of Surgery, Boston, MA, USA.
Objective:
Significant variability exists in the indications for and dosing of cryoprecipitate transfusions. We examined cryoprecipitate transfusions in neonates with a focus on indications, dosing, and the incidence of multi-donor exposure.
Study Design:
In this retrospective study, cryoprecipitate transfusions administered in a single neonatal intensive care unit from January 2022 to December 2024 were reviewed. Patient characteristics, diagnoses, laboratory values, and transfusion details were collected.
Results:
In total, 50 patients received 104 cryoprecipitate transfusions. The median pre-transfusion fibrinogen level was 100 mg/dL (range 15-586), the median dose was 5.9 mL/kg (range 2.1-16.2), and the median increase in fibrinogen was 115 mg/dL (range -5 to 513). Based on the volume administered, 30% of transfusions likely resulted in multi-donor exposure, with no significant difference in the post-transfusion fibrinogen level achieved.
Conclusion:
Significant variation in cryoprecipitate transfusion practices exist, even within a single center. Increasing the weight-based dose of transfusion increases multi-donor exposure without significant clinical benefit.
